Skip to content


Kynamro (mipomersen) is an oligonucleotide pharmaceutical. Mipomersen was first approved as Kynamro on 2013-01-29. It is used to treat familial combined hyperlipidemia in the USA. Kynamro's patents are valid until 2027-01-29 (FDA).
Trade Name Kynamro
Common Name Mipomersen
Indication familial combined hyperlipidemia
Drug Class Antisense oligonucleotides
Get full access now